Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported R&D Expense of $114.00 million for fiscal year 2018.
TEVA PHARMACEUTICAL INDUSTRIES LTD R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2018 | $114.00M | -34.9% |
| 2017 | $175.00M | -58.5% |
| 2016 | $422.00M | +1105.7% |
| 2015 | $35.00M | — |
| 2014 | $0.00 | -100.0% |
| 2013 | $5.00M | -93.2% |
| 2012 | $73.00M | +386.7% |
| 2011 | $15.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2018 | $54.00M | — | — |
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed a decrease of -34.9% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2018 period, TEVA PHARMACEUTICAL INDUSTRIES LTD’s r&d expense has grown by 660.0% (from $15.00 million to $114.00 million).
- The most recent figure is from TEVA PHARMACEUTICAL INDUSTRIES LTD’s fiscal year 2019 report (Form 10-K), filed with the SEC on February 21, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: